2-[(2-oxooxolan-3-yl)sulfanyl]acetic acid | 1094479-23-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-[(2-oxooxolan-3-yl)sulfanyl]acetic acid
• 英文别名: (2-oxo-tetrahydro-furan-3-ylsulfanyl)-acetic acid；2-(2-oxooxolan-3-yl)sulfanylacetic acid
• CAS: 1094479-23-8
• 化学式: C₆H₈O₄S
• mdl: MFCD11646506
• 分子量: 176.193
• InChiKey: GANJLVLIAPOZOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  88.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(2-oxooxolan-3-yl)sulfanyl]acetic acid 、 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 以2.2 mg的产率得到
  参考文献：
  名称：

  [EN] SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS
  [FR] 1,5-NAPHTYRIDINES OU QUINOLÉINES SUBSTITUÉES EN TANT QU'INHIBITEURS D'ALK5

  摘要：

  本公开提供了激活素受体样激酶5（ALK5）的抑制剂。还公开了调节ALK5活性的方法和通过ALK5介导的疾病的治疗方法。

  公开号：

  WO2021102468A1
• 作为产物：
  描述：

  (2-oxo-tetrahydro-furan-3-ylsulfanyl)-acetic acid tert-butyl ester 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 2-[(2-oxooxolan-3-yl)sulfanyl]acetic acid
  参考文献：
  名称：

  [EN] HETEROCYCLIC AMIDES AS ROCK INHIBITORS
  [FR] AMIDES HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE ROCK

  摘要：

  公开号：

  WO2011107608A8

文献信息

• HETEROCYCLIC AMIDES AS ROCK INHIBITORS
  申请人：Leysen Dirk

  公开号：US20120322801A1

  公开（公告）日：2012-12-20

  The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

  本发明涉及新的激酶抑制剂，更具体地说是ROCK抑制剂，包括这些抑制剂的组合物，特别是制药用途的组合物，并且涉及使用这些抑制剂在治疗和预防疾病方面的用途。特别是，本发明涉及新的ROCK抑制剂，包括这些抑制剂的组合物，特别是制药用途的组合物，并且涉及使用这些抑制剂在治疗和预防疾病方面的用途。此外，本发明还涉及治疗和使用所述化合物制造药物的方法，应用于多种治疗适应症，包括性功能障碍、炎症性疾病、眼科疾病和呼吸系统疾病。
• NOVEL ROCK INHIBITORS
  申请人：Amakem NV

  公开号：US20130252975A1

  公开（公告）日：2013-09-26

  The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

  本发明涉及新的激酶抑制剂，更具体地，是ROCK抑制剂，包括这种抑制剂的组合物，特别是制药组合物，并且涉及这种抑制剂在治疗和预防疾病方面的用途。特别地，本发明涉及新的ROCK抑制剂，包括这种抑制剂的组合物，特别是制药组合物，并且涉及这种抑制剂在治疗和预防疾病方面的用途。此外，本发明还涉及使用该化合物的治疗方法和制造药物的用途，适用于多种治疗适应症，包括性功能障碍、炎症性疾病、眼科疾病和呼吸系统疾病。
• Rock inhibitors
  申请人：Amakem NV

  公开号：US08912209B2

  公开（公告）日：2014-12-16

  The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

  本发明涉及新的激酶抑制剂，更具体地涉及ROCK抑制剂，包括这些抑制剂的组合物，特别是制药组合物，以及这些抑制剂在治疗和预防疾病中的用途。特别地，本发明涉及新的ROCK抑制剂，包括这些抑制剂的组合物，特别是制药组合物，以及这些抑制剂在治疗和预防疾病中的用途。此外，本发明涉及治疗方法和使用上述化合物制造药物的方法，适用于多种治疗适应症，包括性功能障碍、炎症性疾病、眼科疾病和呼吸系统疾病。
• Heterocyclic amides as rock inhibitors
  申请人：Leysen Dirk

  公开号：US08815873B2

  公开（公告）日：2014-08-26

  The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

  本发明涉及新的激酶抑制剂，更具体地说是ROCK抑制剂，包括这些抑制剂的组合物，特别是制药组合物，以及在治疗和预防疾病方面使用这些抑制剂的用途。特别地，本发明涉及新的ROCK抑制剂，包括这些抑制剂的组合物，特别是制药组合物，以及在治疗和预防疾病方面使用这些抑制剂的用途。此外，本发明还涉及使用该化合物的治疗方法和用于制造药物的应用，适用于多种治疗适应症，包括性功能障碍、炎症性疾病、眼科疾病和呼吸系统疾病。
• SUBSTITUTED PYRIDINES AND METHODS OF USE
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20210154179A1

  公开（公告）日：2021-05-27

  The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.